Section Arrow
Quote
ERNA.NASDAQ
- Ernexa Therapeutics Inc
(Financial Status)
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 0.2263
-0.0034 (-1.48%)
Day High 
0.261 
Prev. Close
0.2297 
1-M High
0.3048 
Volume 
160.23K 
Bid
0.222
Ask
0.26
Day Low
0.2225 
Open
0.261 
1-M Low
0.221 
Market Cap 
12.00M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.26 
20-SMA 0.27 
50-SMA 0.34 
52-W High 2.625 
52-W Low 0.221 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.26/-10.80
Enterprise Value
12.48M
Balance Sheet
Book Value Per Share
0.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
68.00K
Operating Revenue Per Share
1.95
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.